135590-27-1

Basic information

• Product Name: Benzoic acid, 2-[(chloroacetyl)amino]-5-nitro-
• CAS NO: 135590-27-1
• Molecular Formula: C9H7ClN2O5
• Molecular Weight: 258.618
• Mol File: 135590-27-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-[(chloroacetyl)amino]-5-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-[(chloroacetyl)amino]-5-nitro-(135590-27-1)
• EPA Substance Registry System: Benzoic acid, 2-[(chloroacetyl)amino]-5-nitro-(135590-27-1)

Safety Data

• Hazardous Substances Data: 135590-27-1(Hazardous Substances Data)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 616-79-5 2-amino-5-nitro-benzoic acid 
• 118-92-3 anthranilic acid 
• 14422-49-2 2-chloroacetamidobenzoic acid 

Downstream Products

• 52692-81-6 2-(chloromethyl)-6-nitro-3-phenylquinazolin-4(3H)-one 
• 1613466-03-7 C₂₁H₂₄N₆O₃ 
• 1613466-02-6 C₂₁H₂₄N₆O₃ 
• 1613466-01-5 3-(4-methoxyphenyl)-6-nitro-2-(piperazin-1-ylmethyl)-quinazolin-4(3H)-one 
• 1613465-20-5 3-(3-methoxyphenyl)-6-nitro-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one 
• 1613466-00-4 C₂₀H₂₁N₅O₄ 
• 1613465-14-7 6-nitro-3-phenyl-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one 
• 1613465-98-7 C₂₂H₂₅N₅O₃ 
• 1613465-17-0 2-((4-ethylpiperazin-1-yl)methyl)-3-(4-fluorophenyl)-6-nitroquinazolin-4(3H)-one 
• 1613465-16-9 2-((4-ethylpiperazin-1-yl)methyl)-3-(3-fluorophenyl)-6-nitroquinazolin-4(3H)-one 
• 1613466-05-9 C₁₉H₁₆FN₅O₄ 
• 900134-40-9 3-(2-fluorophenyl)-6-nitro-2-(piperidin-1-ylmethyl)quinazolin-4(3H)-one 
• 900310-82-9 3-(2-fluorophenyl)-2-(morpholinomethyl)-6-nitroquinazolin-4(3H)-one 
• 1613465-19-2 3-(2-fluorophenyl)-6-nitro-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one 

Relevant articles and documents

Development of (E)-2-((1,4-Dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-Amidinophenylbenzamides as Potent Inhibitors of Venezuelan Equine Encephalitis Virus

Venezuelan equine encephalitis virus (VEEV) is an emerging pathogenic alphavirus that can cause significant disease in humans. Given the absence of therapeutic options available and the significance of VEEV as a weaponized agent, an optimization effort wa